ApoC-III and visceral adipose tissue contribute to paradoxically normal triglyceride levels in insulin-resistant African-American women by Sumner, Anne E et al.
 
ApoC-III and visceral adipose tissue contribute to paradoxically
normal triglyceride levels in insulin-resistant African-American
women
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Sumner, Anne E, Jeremy D Furtado, Amber B Courville, Madia
Ricks, Novie Younger-Coleman, Marshall K Tulloch-Reid, and
Frank M Sacks. 2013. “ApoC-III and visceral adipose tissue
contribute to paradoxically normal triglyceride levels in insulin-
resistant African-American women.” Nutrition & Metabolism 10
(1): 73. doi:10.1186/1743-7075-10-73.
http://dx.doi.org/10.1186/1743-7075-10-73.
Published Version doi:10.1186/1743-7075-10-73
Accessed February 19, 2015 3:09:15 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879518
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAARESEARCH Open Access
ApoC-III and visceral adipose tissue contribute to
paradoxically normal triglyceride levels in
insulin-resistant African-American women
Anne E Sumner
1*, Jeremy D Furtado
2, Amber B Courville
3, Madia Ricks
1, Novie Younger-Coleman
4,
Marshall K Tulloch-Reid
4 and Frank M Sacks
2
Abstract
Background: African-Americans are more insulin-resistant than whites but have lower triglyceride (TG) concentrations.
The metabolic basis for this is unknown. Our goal was to determine in a cross-sectional study the effect of insulin
resistance, visceral adipose tissue (VAT) and the apolipoproteins, B, C-III and E, on race differences in TG content of very
low density lipoproteins (VLDL).
Methods: The participants were 31 women (16 African-American, 15 white) of similar age (37±9 vs. 38±11y
(mean±SD), P=0.72) and BMI (32.4±7.2 vs. 29.3±6.0 kg/m
2, P=0.21). A standard diet (33% fat, 52% carbohydrate,
15% protein) was given for 7 days followed by a test meal (40% fat, 40% carbohydrate, 20% protein) on Day 8. Insulin
sensitivity index (SI) was calculated from the minimal model. VAT was measured at L2-3. The influence of race, SI,V A T
and apolipoproteins on the TG content of VLDL was determined by random effects models (REM).
Results: African-Americans were more insulin-resistant (SI:3 . 6±1 . 3v s .5 . 6±2 . 6m U / L
-1.min
-1, P <0.01) with less
VAT (75± 59 vs. 102±71 cm
2, P <0.01). TG, apoB and apoC-III content of light and dense VLDL were lower in
African-Americans (all P < 0.05 except for apoC-III in light VLDL, P=0.11). ApoE content did not vary by race. In
REM, VAT but not SI influenced the TG concentration of VLDL. In models with race, SI, VAT and all apolipoproteins
entered, race was not significant but apoC-III and VAT remained significant determinants of TG concentration in
light and dense VLDL.
Conclusions: Low concentrations of apoC-III and VAT in African-Americans contribute to race differences in TG
concentrations.
Trial registration: ClinicalTrials.gov Identifier: NCT00484861
Keywords: ApoC-III, Visceral adipose tissue, Triglyceride, Apoliprotein C-III, Visceral adiposity, Insulin resistance,
African-Americans, Health disparities
Background
Triglyceride-based screening programs for cardiometa-
bolic risk such as Metabolic Syndrome and Hypertrigly-
cerdemic Waist are based on the principle that insulin
resistance is a fundamental cause of diabetes and cardio-
vascular disease [1,2]. Their key premise is that triglyceride
(TG) concentrations and visceral adiposity are excellent
markers of insulin resistance. However, even though the
prevalence of cardiometabolic disease is higher in African-
Americans than whites, TG concentrations are lower in
African-Americans [3]. Therefore these screening pro-
grams often fail to detect risk in African-Americans [4-6].
As African-American women have lower TG concen-
trations than African-American men, this racial dis-
parity in the efficacy of screening tests is even more
apparent in African-American women [7]. It is unknown
why TG concentrations are not usually elevated in
insulin-resistant African-American women. The influence
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concentrations in African-Americans is a potentially im-
portant but relatively unexplored area [8,9].
Insulin resistance is considered a key factor linking TG
concentrations to visceral adipose tissue (VAT) [10,11]. As
VAT is resistant to the anti-lipolytic effect of insulin, free
fatty acid (FFA) release is increased when the VAT depot is
enlarged. FFA from VAT is used in the synthesis of TG-
rich very low density lipoproteins (VLDL). However, the
metabolic sequence of expanded VAT, insulin resistance
and hypertriglyceridemia may not be applicable to African-
American women. African-American women are more
insulin-resistant than white women but have less VAT [12].
Therefore, the balance between the opposing effects of
insulin resistance and low VAT on TG levels awaits
clarification.
In the fasting state, TG concentration is mostly a
measure of the TG content of VLDL. VLDL represents
a range of particles that vary in density. While both light
and dense VLDL are secreted by the liver, light VLDL
may undergo conversion to dense VLDL [13]. Postpran-
dially, TG concentration represents a combination of
light and dense VLDL as well as chylomicrons which
are TG-rich particles secreted by the intestine [13].
VLDL particles are either cleared by the liver or con-
verted sequentially to intermediate density lipoproteins
(IDL) and low density lipoproteins (LDL) [13].
Each VLDL, IDL and LDL particle has a single apoB
protein. But, apoC-III and apoE are present on some,
but not all lipid particles [14-16]. ApoC-III promotes
hypertriglyceridemia by interfering with hepatic clear-
ance of VLDL [17,18]. In addition, the apoC-III gene
has an insulin response element which negatively influ-
ences gene expression [19-21]. Hence insulin resistance
may promote hypertriglyceridemia by altering apoC-III
production. In contrast to apoC-III, apoE promotes
hepatic clearance of VLDL and therefore, might help
lower TG concentration.
It is challenging to distinguish the independent ef-
fects of insulin resistance, VAT and apolipoproteins on
VLDL-TG. A strategy that simultaneously evaluates
these factors has the potential to elucidate the influ-
ence of each on TG concentrations. Our goal was to
compare the effect of insulin resistance, VATand apoB,
apoC-III and apoE on TG levels in light and dense
VLDL in African-American and white women.
Methods
The study was designed to minimize the confounding
effects of age, obesity and diet. Therefore African-
American and white women of similar age and BMI
were enrolled. In addition, for one week prior to the test
meal, participants consumed the same diet.
Subjects
Recruitment was by flyers, newspaper advertisements and
website. To enroll women had to be 18 to 64 years old, ini-
tiate a call to the study line, self-identify as healthy and
deny a history of diabetes and use of medications, vitamins
or food supplements which affect either glucose or lipid
metabolism. An absence of anemia, liver, kidney or thyroid
dysfunction was confirmed by routine blood tests at the
screening visit. Overall, 35 women attended screening
visits but one white woman was excluded because of the
ingestion of fish oil. Thirty-four non-diabetic women
(17 African-American and 17 whites) were enrolled. Fol-
lowing enrollment, one white woman became pregnant. In
addition, samples from 2 women, 1 African-American and
1 white, could not be analyzed due to sample loss from a
lab accident. The final cohort was 31 women (16 African-
American, age and BMI range 24 to 53 years and 20.6 to
45.9 kg/m
2, respectively, and 15 white, age and BMI range
20 to 49 years and 21.5 to 38.6 kg/m
2, respectively). The
study was approved by the NIDDK Institutional Review
Board. All participants gave informed consent.
Protocol
The study was designed to be completed within 1 month
or less.
At the screening visit a medical history, physical exam-
ination, blood work and an EKG were performed.
At the second visit an insulin-modified frequently
sampled intravenous glucose tolerance test (IM-FSIGT)
was performed [22]. After a 12 hour overnight fast the
participant came to the Clinical Center at 7 AM. Intra-
venous catheters were placed in each antecubital vein.
Dextrose (0.3 g/kg) was administered intravenously over
1 minute. An insulin (0.03 U/kg) bolus was injected at
20 min. Blood samples were taken at −10, -1, 0, 1, 2, 3,
4, 5, 6, 7, 8, 10, 12, 14, 16, 19, 22, 23, 24, 25, 27, 30, 40,
50, 60, 70, 80, 90, 100, 120, 150, 180 min. Glucose and
insulin concentrations were entered into the minimal
model and the insulin sensitivity index (SI) (MinMOD
Millenium v.6.02) calculated [23]. Acute insulin response
to glucose (AIRg) was determined by the area under the
insulin curve between 0 and 10 min for the insulin con-
centration above basal [23]. FFA were modeled mathem-
atically as previously reported [12].
Standard diet and test meal
During the 7 day dietary period, all meals were prepared
in the metabolic kitchen. On weekdays, participants re-
ported to the Clinical Center to be weighed and eat
breakfast. All other meals were provided in a cooler for
consumption off-site. Compliance with picking up daily
food packets and weekend food cooler was 100%.
On day 8, the participant came to the Clinical Center at
7 AM after a 12 hour fast. The test meal was consumed.
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postprandially.
Standard diet
The Mifflin St. Jeor equation multiplied by a physical
activity factor was used to estimate energy needs
[24,25]. The physical activity factor was based on a diet-
ician initiated interview and the National Research
Council Dietary Reference Intake scale [24]. An activity
factor of 1.00-1.39 is for sedentary activity; 1.40-1.59 for
sedentary activity plus 30-60 min of moderate activity;
1.60-1.89 for sedentary activity plus >60 min of daily
moderate activity; and 1.90-2.50 for sedentary activity
plus >60 min of daily moderate activity and >60 min of vig-
orous activity or >120 min of moderate activity.
The macronutrient distribution of the meals was
based on the typical American diet (33% fat, 52%
carbohydrate, 15% protein) [26]. Energy content was
adjusted by the dietitian for weight fluctuations of
1.5 kg from baseline [27]. Mean weight change for
participants between Day 1 and Day 7 of the diet
was −0.67±0.98 kg with no difference by race (P=0.533).
Standardized meal
The meal on Day 8 consisted of 30% of the energy con-
sumed on Day 7. The meal was an egg omelet with
cheddar cheese and butter, plain bagel with cream
cheese and orange juice (40% fat, 40% carbohydrate,
20% protein). Two white participants required
≥950 kcal. To decrease the large volume of orange
juice which would have been required for their meal,
the macronutrient distribution was conserved but
applesauce added.
Body composition
VAT and subcutaneous adipose tissue (SAT) were mea-
sured at L2-3 using a GE HiSpeed Advantage CT/I
scanner (Milwaukee, WI) and analyzed on a SUN work-
station (MEDx image, Sensor System, Inc., Sterling, VA)
[28]. Percent body fat was determined with a dual-
energy X-ray absorptiometry (DXA) scan (Hologic QDR
4500A, Bedford, MA).
Analytic measures
Glucose was determined by the glucose oxidase method
(Yellow Springs Instrument, Yellow Springs, Ohio).
Intra-assay and inter-assay coefficients of variation were
1.5% and 2.5%. Insulin was measured with double anti-
body chemiluminescent sandwich assays (Diagnostic
Products, Los Angeles, California). Intra-assay and inter-
assay coefficients of variation were 1.1% and 4.3%. Lipid
particle number and size was determined by NMR spec-
troscopy (LipoScience, Raleigh, NC).
Ultracentrifugation
Whole plasma samples were separated into density frac-
tions by ultracentrifugation. Light VLDL was isolated by
overlaying 700 μL of sample with 300 μL of d =1.006 g/mL
phosphate buffered saline aqueous solution (PBS)
(Sigma-Aldrich St. Louis, MO) and spinning at 92,470 × g
for 60 min at 15°C in the outer-most row of a Beckman
25-Ti rotor with a Beckman L8-70 M ultracentrifuge
(Fullerton, CA). Top 200±10 μL from each tube was col-
lected by aspiration for analysis. Volume of sample was re-
stored to 1 mL with PBS and the sample mixed by
inversion prior to spinning again at the same conditions
for 16 h. The top 200±10 μL containing the dense VLDL
was collected by aspiration for analysis. IDL was isolated
by increasing the density of the sample to 1.025 g/mL.
Plasma remaining after VLDL aspiration was returned to
800 mcL with PBS, and 193 mcL of 13% KBr and 7 mcL
of H2O were added followed by mixing by repeated inver-
sion. Samples were spun for 16 h under the same condi-
tions as for VLDL isolation and 200±10 μL was aspirated.
LDL was isolated by increasing the density of the sample
to 1.063 g/mL. Plasma remaining after VLDL aspiration
was returned to 800 mcL with PBS, and 135 mcL of 34%
KBr and 65 mcL of H2O were added followed by mixing
by repeated inversion. Samples were spun for 24 h under
the same conditions as for VLDL isolation and 300±
10 μL was aspirated. Four density fractions of plasma were
analyzed: light VLDL (d <1.006 g/mL, Svedberg units of
flotation (Sf) 60∼400), dense VLDL (d <1.006 g/mL, Sf:
20∼60), IDL (1.006 g/mL < d <1.025 g/mL) and LDL
(1.025 g/mL < d <1.063 g/mL).
Lipids and apolipoproteins
Sandwich ELISA procedures using affinity-purified anti-
bodies (Academy Biomedical Company, Inc., Houston, TX)
were performed to determine apoB, apoC-III, and apoE
concentrations in whole plasma and lipoprotein fractions.
Cholesterol and TG were determined enzymatically
(Thermo Scientific, Waltham, MA). Liquid transfer for 96-
well plate loading and ELISA dilutions were handled robot-
ically with Multiprobe II (Perkin Elmer, Waltham, MA).
ELISA and lipid plates were read with a BioTek ELx808iu
96-well plate reader controlled by KCJunior software (Bio-
Tek, Winooski,VT). All assays were completed in triplicate.
For apolipoproteins in lipoprotein subfractions, intra-assay
and inter-assay variations were 5% and 18%; and for TG
and cholesterol intra-assay and inter-assay variation were
3% to 4% and 12% to 17%, respectively.
Statistical analyses
Unless stated otherwise, data are presented as mean± SD.
P-values ≤0.05 were considered significant. Differences by
race were determined with two-tailed unpaired t-test
for continuous variables with a normal distribution and
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comparisons were by chi-square.
Generalized least squares random effects models
(REM) were used to examine race differences in the lipid
response to the meal using measurements from samples
collected both fasting and postprandially. Response vari-
ables (TG fractions) were log transformed to improve
model fit. Breusch and Pagan Lagrangian multiplier test
for REM and a chi-square test for normality were used
to determine whether error terms from the models satis-
fied the assumptions for REM. All models included race
and time as a categorical variable. Models were built by
adding SI and VAT singly and then in combination and
their effect on the coefficient for race examined. ApoB,
apoC-III and apo E were then added singly and in com-
bination to a base model consisting of race, time, SI and
VAT as explanatory variables, to determine if they were
mediators of the relationship between race and TG.
Analyses were performed with STATA, v12.0 (College
Station, Texas).
Results
Demographic and metabolic characteristics of the partici-
p a n t sa r ep r o v i d e di nT a b l e1 .B yd e s i g n ,t h ew o m e nw e r e
similar in age and BMI. There was no difference by race in
percent fat, or waist circumference (WC). However, periph-
eral fat, specifically, thigh circumference was higher in
African-Americans. Adjusting for BMI, African-Americans
had lower VAT but SAT did not differ by race.
In addition, African-Americans were more insulin-
resistant (lower SI) and hyperinsulinemic (higher AIRg)
than whites.
Demographic variables such as family history of dia-
betes, median income, education and smoking did not dif-
fer by race. Even though alcohol intake did not differ by
race, no alcohol was allowed for the 7 days prior to the
test meal.
Effect of the standard diet on TG concentrations
TG concentrations in both the African-American and white
women declined on the controlled-nutrient diet, but the
race difference remained constant (Figure 1). Day 1 of the
diet, fasting TG concentrations in the African-American
and white women were: 70±47 vs. 112 ±60, P= 0.041.
After 7 days on the diet, fasting TG concentrations for the
African-American and white women were: 62±39 vs. 96 ±
45, P=0.031.
Test meal
Fasting Lipids and Apolipoproteins
In whole plasma, levels of total cholesterol and LDL-
cholesterol did not differ by race but TG was lower and
HDL-cholesterol higher in African-Americans (Table 2).
TG levels were lower in light and dense VLDL in African-
Americans than whites, but did not differ in IDL or LDL.
ApoB concentration of light and dense VLDL was lower in
African-Americans than whites, but only reached signifi-
cance in dense VLDL (P=0.010). ApoC-III in dense VLDL
was lower in African-Americans (P=0.014), but apoC-III
Table 1 Demographic and metabolic characteristics of participants
1
Variable African-Americans (n =16) Whites (n =15) P-Value
2
Age (y) 37±9 38±11 0.721
BMI (kg/m
2) 32.4±7.2 29.3±6.0 0.208
Percent fat (%) 38.1±8.3 37.7±7.8 0.892
Waist circumference (cm) 98±17 100±16 0.785
Thigh circumference (cm) 65±10 55±7 0.005
VAT (cm
2)
3 75±59 102±71 0.002
SAT (cm
2)
3 311±188 256±148 0.569
SI (mU/L
-1.min
-1)
4 3.6±1.3 5.6±2.6 0.009
AIRg (mU.l
-1.min)
5 661±383 224±190 <0.001
Family history of diabetes 44% 47% 0.870
Median income $55,000 $55,000 0.819
No college degree 37% 13% 0.124
Graduate school 38% 47% 0.605
Smokers 0/16 2/15 0.311
1Data presented as mean ± SD.
2Continuous variables compared by unpaired t-tests, dichotomous by chi-square.
3P-value adjusted for BMI with regression analyses.
4SI: Insulin sensitivity index.
5AIRg: Acute Insulin Response to glucose.
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did not differ by race in any of the lipoproteins. In
addition, LDL size (21.48±0.70 vs. 21.29±0.66 nm, P=
0.449) and particle number did not differ by race (945±
307 vs. 1148±345 nmol/L, P=0.175).
TG, ApoB, ApoCIII and ApoE concentration during
the test meal In Figure 2 the TG and apolipoprotein con-
centration of each of the lipoproteins are presented at
baseline and 2, 4 and 6 h postprandially. The TG concen-
tration of light and dense VLDL was lower in African-
Americans than whites but did not differ in IDL or LDL
(Figure 2: First Row). Similarly, the apoB concentration in
light and dense VLDL was lower in African-Americans
than whites but did not differ in IDL or LDL (Figure 2,
Second Row). ApoC-III was lower in dense VLDL in
African-Americans than whites, but did not differ by race
in light VLDL, IDL or LDL (Figure 2, Third Row) ApoE
content did not differ by race in any of the lipoproteins
(Figure 2, Fourth Row).
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Figure 1 Fasting TG concentrations at baseline and after 7 days
of the standard diet. Bar graph data presented as mean ± SE.
Notation: a =difference between African-Americans and whites, b =
difference in African-Americans from baseline, *P=<0.05. Difference
in whites before and after 7 day diet was not significant, P=0.18).
Table 2 Fasting lipids and apolipoproteins
1
Variable African-Americans Whites P-Value
2
Whole plasma – Chol (mg/dL) 171 (160, 189) 184 (123, 217) 0.968
Whole plasma – TG (mg/dL) 56 (44, 82) 87 (65, 131) 0.038
Whole plasma - HDL-C (mg/dL) 58 (51, 74) 45 (38, 52) 0.014
Whole plasma - LDL-C (mg/dL) 85 (71, 103) 91 (61, 119) 0.527
Whole plasma - ApoB (mg/dL) 47 (35, 57) 62 (47, 72) 0.058
Whole plasma - ApoCIII (mg/dL) 10.06 (6.58, 14.78) 11.06 (8.32, 13.75) 0.843
Whole plasma - ApoE (mg/dL) 9.01 (5.61, 11.2) 5.94 (5.21, 8.70) 0.133
Light VLDL-TG (mg/dL) 15.8 (6.8, 24.1) 35.9 (19.5, 65.7) 0.014
Light VLDL-apoB (mg/dL) 1.52 (0.66, 3.29) 2.76 (1.59, 6.30) 0.063
Light VLDL-apoCIII (mg/dL) 0.87 (0.53, 1.55) 1.50 0.76, 2.71) 0.304
Light VLDL-apoE (mg/dL) 0.63 (0.35, 1.43) 0.38 (0.30, 0.82) 0.192
Dense VLDL-TG (mg/dL) 7.0 (5.5, 21.0) 22.5 (12.5, 28.7) 0.011
Dense VLDL-apoB (mg/dL) 0.56 (0.21, 1.02) 1.22 (0.79, 2.02) 0.010
Dense VLDL-apoCIII (mg/dL) 0.32 (0.18, 0.69) 0.91 (0.75, 1.43) 0.014
Dense VLDL-apoE (mg/dL) 0.26 (0.06, 0.42) 0.31 (0.12, 0.51) 0.407
IDL-TG (mg/dL) 7.9 (4.5, 11.9) 7.8 (6.2, 14.0) 0.553
IDL-apoB (mg/dL) 2.37 (1.51, 3.91) 4.14 (1.29, 5.05) 0.429
IDL-apoCIII (mg/dL) 0.27 (0.13, 0.41) 0.31 (0.18,0.75) 0.527
IDL-apoE (mg/dL) 0.37 (0.24, 0.49) 0.35 (0.26, 0.59) 0.752
LDL-TG (mg/dL) 11.6 (10.6, 13.7) 11.9 (8.4, 18.1) 0.906
LDL-apoB (mg/dL) 37.6 (29.3, 48.17) 47.8 (39.1, 59.2) 0.123
LDL-apoCIII (mg/dL) 0.86 (0.48,1.70) 0.95 (0.46, 1.24) 0.502
LDL-apoE (mg/dL) 1.14 (0.87, 1.38) 0.93 (0.62, 1.32) 0.323
1Data presented as median (25
th%, 75%).
2Comparisons by Mann–Whitney U test.
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tein fraction Time was entered into every model in
Tables 3 and 4 and always made a significant contribu-
tion (all P <0.01). Therefore “time” is not presented in
each model, but its presence and significance is to be
understood.
In Table 3- Race, SI and VAT were examined in separ-
ate and combined models to determine their influence
on TG levels in light and dense VLDL, IDL and LDL.
Model A-Race
For light and dense VLDL, race was a significant deter-
minant of the TG concentration (overall R
2 =17% and
16% respectively, both P <0.05). In contrast, race did
not influence TG concentration in IDL or LDL (both
overall R
2 =2%andP≥ 0.7).
Model B-Race and SI
For light and dense VLDL, with race and SI in the
model, both were significant determinants of TG con-
centration; overall R
2 was 30% and 25% respectively
(both P≤ 0.05).
Neither race nor SI contributed significantly to the TG
concentration of IDL or LDL; overall R
2 was 9% and
10% respectively.
Model C-Race and VAT
For light and dense VLDL, when race and VAT were the
two independent variables, both were significant contrib-
utors to the TG content of light and dense VLDL. Im-
portantly, the overall R
2 for these models were higher at
47% and 40% than for the preceding model in which the
two independent variables were race and SI.
VAT was a predictor of the TG content of IDL. How-
ever, neither race nor VAT were determinants of the TG
content of LDL.
Model D-Race, SI and VAT
With race, SI and VAT included as independent vari-
ables, VAT was a significant determinant of the TG con-
tent of light and dense VLDL lipoprotein, but SI was not.
Furthermore, the overall R
2 for light and dense VLDL
were 50% and 42%. These values are essentially un-
changed from the model with only race and VAT.
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Figure 2 TG and apolipoprotein concentration of each of the lipoproteins at baseline and 2, 4 and 6 hours postprandially. Columns
present: light VLDL, dense VLDL, IDL and LDL. The rows present the TG, ApoB, ApoC-III and ApoE concentration in each lipoprotein. Data is from
random effect multiple models constructed to determine the effect of race on the TG, ApoB, ApoC-III and ApoE content of each lipoprotein. The
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nificant contribution to the TG content of IDL or LDL.
In Table 4- apoB, apoC-III and apoE are added to the
baseline model of race, SI and VAT and examined separ-
ately (Models A-C) and then together (Model D). In all
models with light and dense VLDL as dependent vari-
ables, VAT was a significant determinant of TG concen-
tration but SI was not.
Model A-Race, SI , VAT and apoB
ApoB concentration was a significant determinant of TG
the concentration of light and dense VLDL, IDL and LDL.
Model B-Race, SI , VAT and apoC-III
ApoC-III was a significant determinant of the TG concen-
tration of light and dense VLDL and IDL but not LDL.
Model C-Race, SI , VAT and apoE
ApoE was a significant determinant of the TG concen-
tration of light and dense VLDL and IDL but not LDL.
Model D-Race, SI , VAT, apoB, apoC-III and apoE
In the combined models, race was not a significant con-
tributor to the TG content of any of the lipoproteins.
ApoB was a significant determinant of the TG content
of only 2 lipoproteins: light VLDL and LDL. ApoC-III
was the only apolipoprotein to be a significant determin-
ant of the TG content of 3 lipoproteins, light and dense
VLDL and IDL. ApoE was a significant determinant of
TG content of only 2 lipoprotein particles: dense VLDL
and IDL. The overall R
2 in these models was higher than
for the models with only one apolipoprotein.
Discussion
By analyzing the combined effect of race, insulin resist-
ance, VAT and the apolipoproteins, we found that the
most consistent determinants of the TG content of light
and dense VLDL were VAT and apoC-III concentration.
In the combined model, ApoB was a determinant of the
TG content of light VLDL and apoE was a determinant
of the TG content of dense VLDL. However, only apoC-
III and VAT were significant determinants of the TG
concentration in both light and dense VLDL. Therefore
the absence of elevated triglycerides levels in African-
American women despite the presence of insulin re-
sistance may be explained, at least in part, by the
combination of low VATand low apoC-III concentrations.
By having SI and VAT in the same model, we were able
to test in a combined population of African-American and
white women the opposing effects of low VAT and insulin
resistance on the TG concentration of VLDL particles.
When VATand insulin resistance were entered into separ-
ate models, each was an important determinant of TG
concentration. However, when insulin resistance and VAT
were entered into the same model, the effect of VAT on
TG concentration in VLDL particles was significant but
the effect of insulin resistance was not. In essence, the ef-
fects of insulin resistance and VAT in whites are difficult
to separate because they are elevated in tandem and highly
correlated. In African-Americans, insulin resistance and
VAT are not elevated in tandem and therefore the oppor-
tunity to distinguish between the effects of each is pro-
vided. In short, low VAT in African-Americans appears to
provide protection from the hypertriglyceridemia expected
from insulin resistance.
Table 3 Random effects model to determine influence of time
1, race
2, insulin resistance and VAT on TG levels
TG – Light VLDL TG – Dense VLDL TG – IDL TG – LDL
Model Variables β-coef SE P-val Variables β-coef SE P-val Variables β-coef SE P-val Variabl β-coef SE P-val
AR
2 = 17% R
2 =16% R
2 =2% R
2 =2 %
Race −0.75 0.32 0.02 Race −0.57 0.26 <0.01 Race −0.05 0.19 0.78 Race 0.07 0.16 0.69
R
2 = 30% R
2 =25% R
2 =9% R
2 =10%
B Race −1.15 0.33 <0.01 Race −0.83 0.28 <0.01 Race −0.20 0.20 0.32 Race −0.07 0.18 0.71
SI
3 −0.19 0.07 <0.01 SI −0.12 0.06 0.05 SI −0.07 0.05 0.11 SI −0.06 0.04 0.11
R
2 = 47% R
2 =40% R
2 =14% R
2 =2 %
C Race −0.52 0.25 0.04 Race −0.41 0.22 0.07 Race 0.03 0.18 0.89 Race 0.08 0.17 0.66
VAT
4 0.66 0.14 <0.01 VAT 0.47 0.13 <0.01 VAT 0.21 0.10 0.03 VAT 0.03 0.09 0.78
R
2 = 50% R
2 =42% R
2 =17% R
2 =10%
D Race −0.76 0.29 <0.01 Race −0.55 0.26 0.04 Race −0.08 0.21 0.69 Race −0.09 0.19 0.66
SI −0.10 0.06 0.10 SI −0.06 0.06 0.31 SI −0.05 0.05 0.33 SI −0.07 0.04 0.12
VAT 0.57 0.15 <0.01 VAT 0.42 0.13 <0.01 VAT 0.18 0.11 0.10 VAT −0.03 0.10 0.78
1Time is significant in every model (P < 0.01).
2Whites are the referent group.
3SI: Insulin sensitivity index.
4VAT: Visceral Adipose Tissue.
The overall R
2 for each model is presented.
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http://www.nutritionandmetabolism.com/content/10/1/73Table 4 Random effects model to determine influence of apoproteins along with time
1, race
2, VAT and insulin resistance on TG levels
TG – Light VLDL TG – Dense VLDL TG – IDL TG – LDL
Model Variables β-coef SE P-val Variables β-coef SE P-val Variables β-coef SE P-val Variables β-coef SE P-val
R
2=61% R
2=55% R
2=27% R
2=29%
Race -0.52 0.25 0.04 Race -0.21 0.25 0.41 Race 0.04 0.21 0.84 Race 0.02 0.18 0.90
AS I
3 -0.09 0.05 0.11 SI <0.01 0.05 0.98 SI -0.02 0.05 0.68 SI - 0.06 0.04 0.13
VAT 0.46 0.13 <0.01 VAT 0.35 0.12 <0.01 VAT 0.12 0.10 0.23 VAT - 0.10 0.09 0.28
ApoB 0.16 0.05 <0.01 ApoB 0.31 0.10 <0.01 ApoB 0.06 0.03 0.04 ApoB 0.01 0.01 <0.01
R
2=63% R
2=60% R
2=42% R
2=11%
Race -0.69 0.23 <0.01 Race -0.13 0.23 0.59 Race 0.13 0.19 0.48 Race - 0.09 0.20 0.63
BS I -0.08 0.05 0.12 SI -0.01 0.05 0.81 SI 0.01 0.04 0.75 SI - 0.06 0.04 0.14
VAT 0.47 0.12 <0.01 VAT 0.37 0.11 <0.01 VAT 0.10 0.09 0.27 VAT - 0.03 0.10 0.79
ApoCIII 0.37 0.09 <0.01 ApoCIII 0.61 0.15 <0.01 ApoCIII 1.10 0.31 <0.01 ApoCIII 0.07 0.12 0.58
R
2=58% R
2=67% R
2=35% R
2=12%
Race -0.88 0.26 <0.01 Race -0.36 0.19 0.05 Race -0.09 0.19 0.62 Race -0.03 0.21 0.90
CS I -0.09 0.06 0.11 SI -0.02 0.04 0.71 SI -0.05 0.04 0.27 SI -0.06 0.04 0.15
VAT 0.56 0.13 <0.01 VAT 0.43 0.09 <0.01 VAT 0.08 0.10 0.42 VAT < 0.01 0.10 0.94
ApoE 0.57 0.21 <0.01 ApoE 1.72 0.31 <0.01 ApoE 1.03 0.36 <0.01 ApoE -0.09 0.10 0.39
R
2=66% R
2=72% R
2=49% R
2=34%
Race -0.38 0.26 0.15 Race 0.01 0.19 0.97 Race 0.10 0.18 0.58 Race 0.12 0.19 0.53
DS I -0.04 0.05 0.48 SI 0.04 0.04 0.31 SI <0.01 0.04 0.96 SI - 0.05 0.04 0.21
VAT 0.36 0.13 <0.01 VAT 0.33 0.09 <0.01 VAT 0.04 0.09 0.65 VAT - 0.07 0.09 0.44
ApoB 0.12 0.05 0.02 ApoB 0.13 0.08 0.12 ApoB 0.04 0.02 0.13 ApoB 0.02 0.01 < 0.01
ApoCIII 0.18 0.04 <0.01 ApoCIII 0.27 0.05 <0.01 ApoCIII 0.42 0.15 <0.01 ApoCIII 0.02 0.03 0.59
ApoE 0.08 0.22 0.72 ApoE 1.07 0.33 <0.01 ApoE 0.73 0.33 0.03 ApoE -0.13 0.09 0.16
1Time is significant in every model (P < 0.01).
2Whites are the referent group.
3SI: Insulin sensitivity index.
The overall R
2 for each model is presented.
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3VAT is an important source of FFA for the liver. The
reason low VAT may mitigate the hypertriglyceridemic
effect of insulin resistance, could be related to the influ-
ence of VAT on hepatic fat content. Although in our in-
vestigation we did not measure of hepatic fat, the Dallas
Heart Study has demonstrated that low VAT is highly
correlated with low hepatic fat [29]. If VAT is low in
African-Americans this could lead to a paucity of hep-
atic fat and it is reasonable to postulate that without suf-
ficient substrate, insulin resistance cannot promote
overproduction of VLDL-TG by the liver.
In addition to VAT, apoC-III has an important influence
on TG concentrations. In our study apoC-III appeared to
be the apoliprotein with the widest impact on the TG con-
centration of VLDL. When all three apolipoproteins were
entered into a single model, apoC-III was the only apopro-
tein to significantly influence the TG content of both light
and dense VLDL. Therefore, the low apoC-III levels in
African-Americans may contribute to the race difference
in VLDL-TG content. From the perspective of cardiovas-
cular disease, it is important to appreciate that the apoCIII
content of LDL did not differ by race. LDL with apoC-III is
the LDL subfraction which most strongly predicts cardio-
vascular disease [30,31]. Therefore, for African-Americans
low apoC-III concentrations in VLDL particles may not
translate into either low concentrations of apoC-III in LDL
or cardioprotection.
At baseline, there was no race difference in the con-
centration of apoE in whole plasma, light or dense VLDL
or LDL. Yet, in the full model after adjusting for race, in-
sulin sensitivity, VAT, and all three apolipoproteins, apoE
was significantly associated with TG concentration in
only two lipid particles, dense VLDL and IDL. The lack
of association between apoE and TG in light VLDL may
be due in part to the fact that apoE facilitates the clear-
ance of lipoproteins from circulation via the hepatic
LDL-receptor [32].
The two major limitations of the study are the lack of
kinetic data and the sample size. Without kinetic data
we are unable to speculate whether TG concentrations
are lower in African-Americans than whites because of
decreased secretion or increased clearance or both. The
sample size of 31 has the potential to predominantly cre-
ate Type 2 errors, meaning that we are unable to detect
race differences in certain variables which a larger com-
parison might have detected. Yet, a major strength of
study is how similar the African-American and white
women were in age, BMI, family history of diabetes and
socioeconomic factors. An additional strength is that the
women consumed a diet with the same distribution of
nutrients for one week prior to the test meal. However,
we did not collect data on the habitual diet of the partic-
ipants. In addition, insulin resistance was measured
while the participants were consuming their habitual diet
while lipid parameters were obtained after 7 days on the
standard diet. Nonetheless, we know of no similar investi-
gation of race differences in TG levels which has placed
the enrollees on a nutrient controlled diet for 1 week prior
to determining the influence of apolipoproteins, insulin re-
sistance and visceral fat on fasting and postprandial levels
of TG. Further, the maintenance of the race difference in
TG concentration in African-American and white women
while on the same diet, suggests that the race difference in
TG concentration is independent of diet as reported previ-
ously in the Omni Study [33].
Conclusion
It has long been a clinical conundrum as to why triglyceride
(TG) levels are normal in African-Americans despite high
rates of obesity, insulin resistance and cardiovascular dis-
ease. In the past research on race differences in TG concen-
tration has focused mainly on the role of insulin resistance,
our data strongly supports expanding the scope of study to
include an evaluation of the influence of VATand apoC-III.
With more information from a wider scope of investigation,
more effective paradigms can be developed to detect early
cardiovascular risk in African-Americans may be identified.
Overall, our investigation provides data on why not includ-
ing TG levels in screening for cardiovascular disease is ap-
propriate in African-Americans. Our long term goal is the
minimization of health disparities in cardiometabolic dis-
ease through better screening.
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